ABEO

Abeona Therapeutics Inc. [ABEO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ABEO Stock Summary

Top 10 Correlated ETFs

ABEO

Top 10 Correlated Stocks

ABEO

In the News

ABEO Financial details

Company Rating
-
Market Cap
206.53M
Income
-54.19M
Revenue
3.5M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
84
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-4.92
Forward P/E
-
PEG
1.36
P/S
39.09
P/B
6.33
P/C
-
P/FCF
-3.31
Quick Ratio
6.65
Current Ratio
6.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.59
EPS next Y
-
EPS next Q
-
EPS this Y
-37.53%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
35.42%
-
-
-
-
SMA20
14.49%
SMA50
31.15%
SMA100
19.18%
Inst Own
-
Inst Trans
-
ROA
-43%
ROE
-148%
ROC
-0.81%
Gross Margin
52%
Oper. Margin
-1313%
Profit Margin
-795%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.73-9.01
52W High
-31.56%
52W Low
+208%
RSI
50.46
Rel Volume
1.08
Avg Volume
341.48K
Volume
368.48K
Perf Week
-4.35%
Perf Month
-10.33%
Perf Quarter
9.41%
Perf Half Y
2.5%
-
-
-
-
Beta
1.479
-
-
Volatility
0.19%, 0.41%
Prev Close
-1.44%
Price
6.16
Change
-0.65%

Something similar

Top by Market Cap
APC.DE
0YXG.L
ABEC.DE
VTSAX
BRH.DE
Top Correlated ETFs
IEFM.L
EUFN
UKSR.L
HSUK.L
CS1.L
Top Correlated Stocks
0H7R.L
JEL.L
TRU.L
SYANY
MCVT
Similar Market Cap
GRX
SJG.L
INDOSOLAR.NS
PEBK
VIXY

Company Profile

Healthcare Biotechnology
  • Volume Average 341.48K
  • Market Capitalization 206.53M
  • Employee 84
  • CEO Dr. Vishwas Seshadri M.B.A., Ph.D.
  • Headquarters New York,NY,US
  • IPO Date 1980-09-19
  • Website https://www.abeonatherapeutics.com

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.